Skip to content
drillr.ai
Sign up

TMO

THERMO FISHER SCIENTIFIC INC.

NYSE · Healthcare · Medical - Diagnostics & Research · US

$700.02
+0.24%
Ask drillr

  • Aug 13, 2026, 12:15 UTC

    Vietnam's National Innovation Center (NIC) and Thermo Fisher Scientific agreed to cooperate on developing shared research and technology infrastructure in Vietnam, aiming to reduce technology access costs and strengthen the country's innovation ecosystem.

    Source:

  • Aug 12, 2026, 12:13 UTC

    Astorg completed its acquisition of Thermo Fisher Scientific's global microbiology business, establishing an independent diagnostics company led by CEO Dirk Bontridder.

    Source:

  • Jul 24, 2026, 12:30 UTC

    Thermo Fisher Scientific launched the Thermo Scientific InstaFlux integrated media-on-demand enrichment workflow for food microbiology laboratories globally.

    Source:

  • Jul 23, 2026, 10:00 UTC

    Thermo Fisher Scientific reported its second quarter 2026 financial results, with revenue of $11.99 billion, GAAP EPS of $4.68, and adjusted EPS of $6.03.

    Source:

  • Jul 22, 2026, 06:32 UTC

    ImmuPharma PLC appointed Thermo Fisher Scientific to develop and manufacture the finished form of its experimental diabetes treatment Kapiglucagon.

    Source:

  • Jul 15, 2026, 15:45 UTC

    San Diego Zoo Wildlife Alliance appointed Annie Fitzgerald as chief operating officer and Allyson Carr as chief human resources officer.

    Source:

  • Jul 9, 2026, 21:00 UTC

    Thermo Fisher Scientific Inc. announced a quarterly cash dividend of $0.47 per common share, payable on October 15, 2026, to shareholders of record as of September 15, 2026.

    Source:

  • Jul 7, 2026, 12:30 UTC

    Thermo Fisher Scientific received FBI approval for its RapidINTEL Plus Cartridge to generate DNA profiles eligible for national CODIS searches.

    Source:

  • Jul 2, 2026, 11:00 UTC

    Arcturus Therapeutics announced a strategic collaboration with Thermo Fisher Scientific to support Phase 3 development and potential commercialization of ARCT-032 for cystic fibrosis.

    Source:

  • Jul 2, 2026, 00:00 UTC

    Arcturus Therapeutics signed a Master Services Agreement with Thermo Fisher Scientific for development services for ARCT-032, an mRNA therapeutic for cystic fibrosis, with Thermo Fisher contributing up to $40 million in clinical manufacturing services and Arcturus engaging PPD for up to $40 million in CRO services.

  • Jun 29, 2026, 08:07 UTC

    genedrive PLC signed a collaboration agreement with Thermo Fisher Scientific to develop a high-throughput laboratory test.

    Source:

  • Jun 16, 2026, 00:00 UTC

    GeneDx Holdings Corp. appointed Mark Gardner as President, effective June 15, 2026.

    Source:

  • Jun 1, 2026, 12:30 UTC

    Thermo Fisher Scientific expanded its Orbitrap mass spectrometry platforms, AI-enabled software and integrated workflows at the ASMS 2026 conference.

    Source:
← PreviousPage 2